Google
Trusted Resources: News & Events
Latest announcements and gatherings
Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease
Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd., a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease.
The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combines attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body.
+myBinderRelated Content
-
Development and Feasibility Testing of the Comfort Ability Program for Sickle Cell Pain: A Patient-Informed, Video-B...Objective: Even with optimized medical...
-
SCDAA News Advisory: SCDAA Statement on Exa-cel Gene TherapyOn October 31, 2023, the Food and Drug A...
-
First World Cord Blood Day on Nov. 15 to Highlight Cord Blood Uses, Stem Cell ResearchThe inaugural World Cord Blood Day on No...
-
New Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell AnemiaResearchers at New York’s Weill Cornel...
-
World’s Largest Sickle Cell Disease Stem Cell Library UnderwayScientists in Boston are creating a stem...
-
A new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
Gene Therapy: An Experimental Technique to Treat Genetic DiseasesGene therapy is an experimental techniqu...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.